TVTXTravere Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Travere Therapeutics, Inc. against SPDR S&P Biotech ETF holdings — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TVTXEsta | $4.6B#6 | — | 203.9x#7 | 9.4x#1 | 110.5%#2 | 92.1%#1 | -12.8%#1 | -113.1%#7 | — | — | — | — |
| TWST | $8.8B#1 | — | 19.7x#6 | 23.3x#2 | 20.3%#3 | 62.8%#2 | -36.2%#2 | -17.4%#2 | -41.4%#1 | — | — | — |
| VKTX | $3.4B#7 | — | 5.8x#2 | — | — | -227.1%#8 | — | -61.1%#6 | — | — | -26.0%#1 | — |
| PRAX | $7.9B#3 | — | 5.9x#3 | — | -100.0%#5 | -65.6%#6 | — | -22.6%#4 | — | — | — | — |
| ERAS | $5.2B#4 | — | 14.3x#5 | — | — | 23.0%#3 | — | -34.4%#5 | — | — | — | — |
| SLS | $1.8B#8 | — | 12.9x#4 | — | -100.0%#5 | 13.0%#4 | — | -19.5%#3 | — | — | — | — |
| DNTH | $4.7B#5 | — | 4.0x#1 | 2326.4x#4 | -67.3%#4 | -91.1%#7 | -8739.3%#4 | -13.9%#1 | — | — | — | — |
| CYTK | $8.8B#2 | — | — | 99.5x#3 | 376.6%#1 | -33.2%#5 | -695.4%#3 | — | — | — | — | — |
Peer set: top holdings of XBI (SPDR S&P Biotech ETF), the indexed fund holding this stock at its highest weight — a fund manager's grouping, not Tickwind's judgement. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-11-04.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice